Back to
Dr Ellen Bowden-Reid

Dr Ellen Bowden-Reid

Research Associate

PhD, BSc (Hons I)

Medicine & Health
The Kirby Institute

Ellen Bowden-Reid is a Research Associate with the Infection Analytics Program at the Kirby Institute. Through evidence-based research, she will utilise preclinical immunological evidence for vaccine development and approval.

In 2024, she completed a PhD in the area of early drug discovery, where her research focused on developing novel RNA-based therapies for HIV and SARS-CoV-2 using preclinical in vitro models of infection.
Phone
+61 2 9348 2651
E-mail
ebowdenreid@kirby.unsw.edu.au
Location
The Kirby Institute Bidjigal Country Level 5, Wallace Wurth Building High Street, UNSW Sydney Kensington NSW 2052
  • Journal articles | 2025
    Bowden-Reid E; Moles E; Kelleher A; Ahlenstiel C, 2025, 'Harnessing antiviral RNAi therapeutics for pandemic viruses: SARS-CoV-2 and HIV', Drug Delivery and Translational Research, 15, pp. 2301 - 2322, http://dx.doi.org/10.1007/s13346-025-01788-x
    Journal articles | 2024
    Han WM; Sazzad HMS; Bloch M; Baker DA; Roth N; Bowden-Reid E; Smith DE; Hoy JF; Woolley I; Finlayson R; Templeton DJ; Matthews GV; Costello J; Dawson MA; Dawson SJ; Polizzotto MN; Petoumenos K; Yeh P; Dharan NJ; Winter D; Baker D; Lau H; Acklom K; Price S; O'Bryan J; Sinclair B, 2024, 'Age-related clonal hematopoiesis and HIV infection are associated with geriatric outcomes: The ARCHIVE study', Cell Reports Medicine, 5, http://dx.doi.org/10.1016/j.xcrm.2024.101835
    Journal articles | 2023
    Bowden-Reid E; Ledger S; Zhang Y; Di Giallonardo F; Aggarwal A; Stella AO; Akerman A; Milogiannakis V; Walker G; Rawlinson W; Turville S; Kelleher AD; Ahlenstiel C, 2023, 'Novel siRNA therapeutics demonstrate multi-variant efficacy against SARS-CoV-2', Antiviral Research, 217, http://dx.doi.org/10.1016/j.antiviral.2023.105677